JP2023549323A - 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 - Google Patents
治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 Download PDFInfo
- Publication number
- JP2023549323A JP2023549323A JP2023525999A JP2023525999A JP2023549323A JP 2023549323 A JP2023549323 A JP 2023549323A JP 2023525999 A JP2023525999 A JP 2023525999A JP 2023525999 A JP2023525999 A JP 2023525999A JP 2023549323 A JP2023549323 A JP 2023549323A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- enzyme
- fusion protein
- region
- kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152247 | 2020-11-13 | ||
| KR10-2020-0152247 | 2020-11-13 | ||
| PCT/KR2021/016630 WO2022103221A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549323A true JP2023549323A (ja) | 2023-11-24 |
| JPWO2022103221A5 JPWO2022103221A5 (enExample) | 2024-11-25 |
Family
ID=81602509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525999A Pending JP2023549323A (ja) | 2020-11-13 | 2021-11-15 | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405093A1 (enExample) |
| EP (1) | EP4245311A4 (enExample) |
| JP (1) | JP2023549323A (enExample) |
| KR (1) | KR20220065719A (enExample) |
| CN (1) | CN116419760A (enExample) |
| AU (1) | AU2021378707A1 (enExample) |
| CA (1) | CA3196258A1 (enExample) |
| CO (1) | CO2023006437A2 (enExample) |
| IL (1) | IL302858A (enExample) |
| MX (1) | MX2023005580A (enExample) |
| WO (1) | WO2022103221A1 (enExample) |
| ZA (1) | ZA202304534B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250040515A (ko) * | 2023-09-14 | 2025-03-24 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 신규한 동결 건조 제제 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013520996A (ja) * | 2010-03-01 | 2013-06-10 | バイエル・ヘルスケア・エルエルシー | 組織因子経路インヒビター（ｔｆｐｉ）に対する最適化されたモノクローナル抗体 |
| WO2019016487A1 (fr) * | 2017-07-21 | 2019-01-24 | Arkema France | Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs |
| JP2020504131A (ja) * | 2017-01-05 | 2020-02-06 | プロタリクス リミテッド | 安定化α−ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| TWI832818B (zh) * | 2017-07-07 | 2024-02-21 | 南韓商韓美藥品股份有限公司 | 新穎的治療性酵素融合蛋白及其用途 |
| JP7403455B2 (ja) * | 2017-12-22 | 2023-12-22 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規な構造を有する治療学的酵素融合タンパク質及びその用途 |
-
2021
- 2021-11-15 CN CN202180075093.2A patent/CN116419760A/zh active Pending
- 2021-11-15 EP EP21892388.6A patent/EP4245311A4/en active Pending
- 2021-11-15 WO PCT/KR2021/016630 patent/WO2022103221A1/ko not_active Ceased
- 2021-11-15 MX MX2023005580A patent/MX2023005580A/es unknown
- 2021-11-15 JP JP2023525999A patent/JP2023549323A/ja active Pending
- 2021-11-15 IL IL302858A patent/IL302858A/en unknown
- 2021-11-15 AU AU2021378707A patent/AU2021378707A1/en active Pending
- 2021-11-15 CA CA3196258A patent/CA3196258A1/en active Pending
- 2021-11-15 KR KR1020210156861A patent/KR20220065719A/ko active Pending
- 2021-11-15 US US18/036,580 patent/US20230405093A1/en active Pending
-
2023
- 2023-04-19 ZA ZA2023/04534A patent/ZA202304534B/en unknown
- 2023-05-16 CO CONC2023/0006437A patent/CO2023006437A2/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013520996A (ja) * | 2010-03-01 | 2013-06-10 | バイエル・ヘルスケア・エルエルシー | 組織因子経路インヒビター（ｔｆｐｉ）に対する最適化されたモノクローナル抗体 |
| JP2020504131A (ja) * | 2017-01-05 | 2020-02-06 | プロタリクス リミテッド | 安定化α−ガラクトシダーゼを用いた、ファブリー病の治療のための治療レジメン |
| WO2019016487A1 (fr) * | 2017-07-21 | 2019-01-24 | Arkema France | Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs |
Non-Patent Citations (1)
| Title |
|---|
| PLOS ONE, vol. 10, no. 0136442, JPN6025049656, 2015, pages 1 - 15, ISSN: 0005743830 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4245311A4 (en) | 2024-10-30 |
| ZA202304534B (en) | 2024-10-30 |
| EP4245311A1 (en) | 2023-09-20 |
| CO2023006437A2 (es) | 2023-06-09 |
| AU2021378707A1 (en) | 2023-06-01 |
| CN116419760A (zh) | 2023-07-11 |
| CA3196258A1 (en) | 2022-05-19 |
| US20230405093A1 (en) | 2023-12-21 |
| IL302858A (en) | 2023-07-01 |
| MX2023005580A (es) | 2023-05-29 |
| AU2021378707A9 (en) | 2024-07-11 |
| WO2022103221A1 (ko) | 2022-05-19 |
| KR20220065719A (ko) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102851747B1 (ko) | 효소 내재화 조성물 및 방법 | |
| US9458214B2 (en) | Dual function fibroblast growth factor 21 proteins | |
| JP2021507705A (ja) | 新規な構造を有する治療学的酵素融合タンパク質及びその用途 | |
| KR20180120739A (ko) | 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제 | |
| JP7697784B2 (ja) | 新規治療学的酵素融合タンパク質及びその用途 | |
| US20250170227A1 (en) | Conjugated c1 esterase inhibitor and uses thereof | |
| EP2354155B1 (en) | Fusion Proteins for Treatment of CNS | |
| EP4197550A1 (en) | Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors | |
| JP2023549323A (ja) | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 | |
| KR20220009354A (ko) | 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도 | |
| HK40096917A (en) | Use of therapeutic enzyme fusion protein for preventing and treating kidney disease caused or accompanied by fabry's disease | |
| JP2020528756A (ja) | イズロン酸−２−スルファターゼ結合体 | |
| EP3649159A1 (en) | Fusion protein | |
| JP2023549322A (ja) | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴うニューロパチーの予防及び治療用途 | |
| KR20220140443A (ko) | 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물 | |
| KR20220092442A (ko) | 신규한 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도 | |
| HK40096918A (en) | Use of therapeutic enzyme fusion protein in preventing and treating neuropathy attributed to or associated with farbry's disease | |
| US20230390362A1 (en) | Use of trigonal agonist having activities to all of glucagon, glp-1, and gip receptors in treatment of sequelae following respiratory infectious diseases | |
| WO2024137820A1 (en) | Insulin receptor antagonist | |
| KR20230095666A (ko) | 간 표적 물질 및 이의 용도 | |
| JP2025509063A (ja) | α－ガラクトシダーゼＡの融合タンパク質を含む液状製剤 | |
| CN116419766A (zh) | 作用于胰高血糖素、glp-1和gip受体全部的三重激动剂的长效缀合物对抗多发性硬化的治疗用途 | |
| HK40018046A (en) | Novel therapeutic enzyme fusion protein and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241115 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251202 |